ASX:PAB

Patrys Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume250,000 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive PAB News and Ratings via Email

Sign-up to receive the latest news and ratings for Patrys and its competitors with MarketBeat's FREE daily newsletter.


About Patrys

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates live cell nuclei and inhibits mechanisms of DNA repair in target cancer cells. The company also focuses on developing PAT-DX1 as a treatment for metastatic triple negative breast cancer and glioblastoma. In addition, it engages in developing PAT-SC1's target/antigen CD55PAT-SC1, an isoform of the membrane-bound CD55 for the treatment of gastric cancer. Patrys Limited has a collaborative research program with Imagion Biosystems Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis. The company was founded in 2006 and is based in South Melbourne, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.27 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Patrys (ASX:PAB) Frequently Asked Questions

What stocks does MarketBeat like better than Patrys?

Wall Street analysts have given Patrys a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Patrys wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Patrys' earnings last quarter?

Patrys Limited (ASX:PAB) issued its quarterly earnings results on Wednesday, February, 20th. The company reported $0.00 earnings per share (EPS) for the quarter.
View Patrys' earnings history
.

Who are Patrys' key executives?

Patrys' management team includes the following people:
  • Dr. James A. Campbell B.Sc., Ph.D., MBA, MD, CEO & Exec. Director
  • Ms. Melanie Jaye Leydin C.A., B.Bus, CA, Company Sec. (Age 48, Pay $120k)
  • Dr. Deanne Greenwood B.Sc., GAICD, Ph.D., MBA, VP of Bus. Devel. & Intellectual Property

Who are some of Patrys' key competitors?

What other stocks do shareholders of Patrys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Patrys investors own include Woolworths Group (WOW), Proteomics International Laboratories (PIQ), Insurance Australia Group (IAG) and Bendigo and Adelaide Bank (BEN).

What is Patrys' stock symbol?

Patrys trades on the ASX under the ticker symbol "PAB."

How much money does Patrys make?

Patrys has a market capitalization of $0.00 and generates $1.34 million in revenue each year.

What is Patrys' official website?

The official website for Patrys is www.patrys.com.

How can I contact Patrys?

The company can be reached via phone at 61 3 9692 7222.


This page was last updated on 9/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.